Retatrutide 20 mg --- Research Product Overview

**Disclaimer:** This article is provided for educational and research purposes only. [Retatrutide](/catalog/retatrutide-10) research material sold by Viking Labs is intended for laboratory research use only. It is not approved by the FDA or any other regulatory authority for human therapeutic use, and nothing in this article constitutes medical advice or a recommendation for self-administration.

Overview

The Viking Labs 20 mg retatrutide vial is a higher-content lyophilized presentation of the GLP-1R / GIPR / GCGR triple agonist retatrutide (LY3437943), suited to laboratory workflows that require larger working stocks, multi-dose rodent cohorts, or extended-duration in vivo experiments. The peptide identity, sequence, mechanism, and structural features are identical to those described in the Retatrutide 10 mg vial overview; this article focuses on the practical considerations specific to the higher-content presentation. For mechanistic background, also see our retatrutide triple agonist explainer.

Sequence and Structural Notes

Retatrutide is a 39-amino acid lipidated peptide with an Aib2 substitution and a C20 fatty diacid linker for albumin binding. Approximate molecular weight: 4731 Da. The 20 mg vial contains the same active species as the 10 mg vial; only the fill weight and reconstitution volumes differ. See Coskun et al. (2022) for the full structural rationale and receptor engineering history.

Mechanism of Action

Retatrutide is a balanced agonist at GLP-1R, GIPR, and GCGR. GLP-1R and GIPR engagement drive incretin-class effects on insulin secretion and appetite signaling; GCGR engagement contributes to energy expenditure, hepatic lipid oxidation, and lipolysis. The combination is hypothesized to produce metabolic effects that exceed those of GLP-1 or GLP-1/GIP co-agonists in preclinical models. See the 10 mg overview for receptor pharmacology detail.

Comparator Peptides --- Triple- vs. Dual- vs. Mono-Agonists

While the retatrutide molecule itself is identical between the 10 mg and 20 mg presentations, comparing it to its incretin-class siblings remains a frequent reference question for researchers planning extended-duration cohort studies. Our retatrutide vs. semaglutide vs. tirzepatide write-up provides the full comparison; key points relevant to the 20 mg vial follow.

Cohort planning under triple-agonist pharmacology. A 20 mg vial typically supports a 12-20 mouse DIO cohort dosed every 3 days for 8 weeks at the high preclinical dose range. By contrast, a comparable semaglutide cohort study at matched receptor occupancy would draw less material per cohort because semaglutide is more potent on a mass basis at GLP-1R alone --- but retatrutide cohorts often run higher dose-arms to fully engage the GCGR axis, offsetting the apparent potency advantage. Tirzepatide cohorts (tirzepatide dual agonist overview) typically draw similar mass per cohort to retatrutide.

Pharmacokinetic comparator notes. All three peptides support every-3-days or weekly dosing in rodent cohorts. Retatrutide's reported terminal half-life in DIO mice is approximately 14 hours, vs. 16 hours for semaglutide and 9 hours for tirzepatide; the shorter rodent half-life relative to humans reflects species-specific albumin binding kinetics. Researchers building extended-duration cohorts should plan dose intervals to maintain trough concentrations consistent with their study design.

Endpoint comparisons. For body-composition endpoints (DEXA, indirect calorimetry, hepatic triglyceride), retatrutide produces the largest effect sizes per cohort but also the largest inter-animal variance --- reflecting differential GCGR responsiveness across DIO mouse lines. Cohort sizes of n greater than 12 are commonly recommended for retatrutide endpoints, which is the primary practical reason researchers choose the 20 mg presentation over the 10 mg.

Deeper Preclinical Breakdown

The mechanistic preclinical evidence for retatrutide is summarized in the 10 mg overview; here we focus on three studies that bear directly on extended-duration cohort design.

Coskun et al. (2022) --- 28-day DIO mouse cohort. Methodology: male DIO C57BL/6 mice fed 60% kcal HFD for 16 weeks were randomized to vehicle, retatrutide 0.1/1/10 nmol/kg, semaglutide 10 nmol/kg, or pair-fed control, with subcutaneous dosing every 3 days for 28 days. Key result: high-dose retatrutide produced 22% body-weight reduction vs. 9% for semaglutide and 16% for pair-fed control, indicating the energy-expenditure component is mechanistically distinct from caloric reduction. Limitation: only male mice; sex-specific differences in GCGR responsiveness were not characterized.

Coskun et al. (2022) supplementary data --- cynomolgus monkey PK. Methodology: cynomolgus monkeys were dosed at 0.4-3 nmol/kg subcutaneously, with serial plasma sampling for 14 days. Key result: terminal half-life of approximately 160 hours in monkeys, supporting once-weekly dosing in larger species. Limitation: small cohort (n=3-4 per dose); receptor occupancy was inferred rather than measured directly.

Jastreboff et al. (2023, NEJM PMID 37235529) --- Phase 2 obesity trial. While clinical, this trial validates the predictive value of the DIO mouse cohort model: the 24.2% body-weight reduction at the highest dose corresponds reasonably well to the 22% reduction observed in the matched preclinical cohort. Limitation: 48-week follow-up; durability and weight regain after discontinuation were not fully characterized in the primary report.

Preclinical Research Summary

The preclinical evidence base for retatrutide is summarized in the 10 mg vial overview. Briefly, DIO mice, obese cynomolgus monkeys, and rat metabolic models have shown dose-dependent reductions in body weight, fat mass, and hepatic triglyceride content, with corresponding improvements in glucose tolerance and lipid panels. Phase 2 clinical data (Jastreboff et al., 2023) established the human dose-response profile.

The 20 mg vial is particularly relevant for researchers running:

• Multi-week chronic dosing studies in rodent cohorts
• Comparative dose-titration experiments against tirzepatide and semaglutide
• Indirect calorimetry studies requiring sustained dosing
• Hepatic lipid metabolism studies in extended-feeding NAFLD/NASH models

Common Research Applications

The 20 mg presentation is suited to applications where the 10 mg fill weight would force inconvenient mid-study reconstitutions or impractical working-stock dilutions. Typical uses include extended in vivo dosing series, large rodent cohorts (n greater than 12), and biorepository workflows where a single lot is preferred for reproducibility across an entire experiment. See our research peptide buying guide for guidance on lot consistency and vendor evaluation.

Formulation Considerations

The 20 mg vial follows the same formulation conventions as the 10 mg vial: lyophilized cake from acetate-buffered solution at pH 7.0-7.5, reconstituted with sterile bacteriostatic water or saline at 1-5 mg/mL. The higher peptide mass per vial introduces specific considerations for cohort workflows.

Reconstitution volume planning. A 20 mg vial reconstituted at 5 mg/mL yields 4 mL of working stock, which is typically sufficient for 12-20 dose preparations across a 4-8 week study. Researchers should plan reconstitution volume to match the entire planned use window, since post-reconstitution stability (28-42 days at 2-8 degrees C) bounds the practical use window.

Aliquoting after reconstitution. Some workflows aliquot reconstituted retatrutide into single-use volumes for short-term -20 degrees C storage, which preserves main-peak purity for 60-90 days but introduces freeze-thaw artifacts in the lipidated species. This approach should be validated against in-house stability data before applying to high-stakes endpoints.

Common [COA](/research/glossary#coa) impurities. As with the 10 mg vial: des-amidation at internal Asn/Gln (less than 0.5% combined), acylation-related synthesis byproducts (0.1-1.0% range), and trace Trp oxidation. The COA should report counterion content and endotoxin level explicitly. See our reading HPLC COA reference for interpretation.

Research-Context Dosing Ranges

In published preclinical literature, retatrutide doses in DIO mouse cohorts have spanned 0.1 to 10 nmol/kg administered subcutaneously every 3 days; in non-human primate studies, 0.4-3 nmol/kg/week is typical. For an 8-week DIO mouse cohort of n=15 dosed at 10 nmol/kg every 3 days, total peptide consumption is approximately 4.5 mg, fitting comfortably within a 20 mg vial with reserve. These ranges are provided strictly as references to published research literature and are not recommendations for human use.

Handling, Reconstitution, and Storage

Storage and reconstitution practices are identical to those for the 10 mg vial:

• Store lyophilized vial at -20 degrees C protected from light
• Reconstitute with sterile bacteriostatic water; gentle inversion preferred over vortexing
• Once reconstituted, store at 2-8 degrees C; typically stable 28-42 days under aseptic conditions
• Avoid repeated freeze-thaw of reconstituted material
• For very dilute working stocks, low-binding tubes and 0.1% BSA carrier reduce adsorption losses

For the higher-content vial specifically, plan reconstitution volume to produce a working concentration appropriate to the entire planned use window. Aliquoting after reconstitution into single-use volumes (then storing at -20 degrees C briefly) is acceptable in some workflows but should be validated against the laboratory's stability data. Our peptide reconstitution guide covers the underlying principles.

HPLC Purity and Lab Specifications

• HPLC purity: greater than or equal to 98.0% (RP-HPLC, 214 nm)
• Identity: ESI-MS or MALDI-TOF, theoretical mass within 1 Da
• Counterion content (acetate/TFA) reported on COA
• Endotoxin: less than 5 EU/mg
• Water content: typically less than 5% by Karl Fischer titration

For interpretive guidance, see How to read a peptide COA.

Cross-References --- Related Viking Labs Research

For continued reading on retatrutide and the incretin research peptide class:

• Retatrutide 10 mg vial overview
• Semaglutide GLP-1 research overview
• Retatrutide triple agonist explained
• Peptide storage and stability
• Understanding peptide purity
• WADA prohibited list 2026

*Provided for laboratory research purposes only. Not for human or veterinary use.*